HealthcareServices

Opioid-Induced Constipation Treatment Industry Insights: Market Forecast to 2029

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Opioid-Induced Constipation Treatment Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The opioid-induced constipation treatment market has experienced significant expansion in recent years. Its size is expected to increase from $1.78 billion in 2024 to $1.9 billion in 2025, progressing at a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this historical growth include the expanding geriatric population, personalized OIC treatments, availability of effective OIC drugs, increasing prevalence of opioid use, and rising prevalence of gastrointestinal disorders.

The opioid-induced constipation treatment market is anticipated to show significant expansion over the next few years. It is predicted to reach $2.42 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period is primarily driven by initiatives for expedited drug approvals, a rise in opioid analgesic prescriptions, substantial investments in the research and development of novel treatments, and an uptick in the creation of biologics. Noteworthy trends for the forecast period encompass enhanced patient education and awareness, the development of targeted therapies, non-pharmacological interventions, innovations in biotechnology, and increased capital investment.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Which Drivers Are Shaping The Opioid-Induced Constipation Treatment Industry’s Market Share?

The increasing administration of opioids for both cancer and non-cancer pain is expected to drive the expansion of the opioid-induced constipation treatment market. Cancer pain describes discomfort associated with cancer and its various treatments, while non-cancer pain denotes discomfort stemming from conditions unrelated to cancer. The necessity to effectively manage moderate to severe pain propels the use of opioids for cancer and non-cancer pain, considering aspects such as pain intensity and duration, patient responses to other therapies, and the broader aim of enhancing quality of life while minimizing potential addiction risks and adverse effects. Opioid-induced constipation (OIC) treatment provides relief to patients experiencing cancer and non-cancer pain by alleviating constipation resulting from opioid use, thus improving general comfort, adherence to pain management regimens, and overall quality of life without diminishing pain relief. For example, according to the Government of Canada in May 2021, up to 8.3 million Canadians are projected to experience chronic pain by 2025, a figure anticipated to rise to 9.0 million by 2030. Therefore, the growing use of opioids for cancer and non-cancer pain is a significant factor contributing to the growth of the opioid-induced constipation treatment market.

What Are The Different Segment Classifications Within The Opioid-Induced Constipation Treatment Market?

The opioid-induced constipation treatmentmarket covered in this report is segmented –

1) By Drug Class: Laxatives; Peripherally Acting µ-opioid Receptor Antagonists; Serotonin Receptor Agonists; Prostaglandin

2) By Type: Oral; Parenteral

3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives; Stimulant Laxatives; Bulk-Forming Laxatives

2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol; Methylnaltrexone; Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride; Tegaserod

4) By Prostaglandin: Lubiprostone

What Trends Are Expected To Drive The Opioid-Induced Constipation Treatment Market?

Leading corporations engaged in the opioid-induced constipation treatment market are implementing strategic partnerships to innovate new medicines. These strategic alliances assist opioid-induced constipation treatment companies by consolidating resources and expertise, strengthening research and development capacities, widening market penetration, and speeding up commercialization, ultimately stimulating innovation and expansion within the opioid-induced constipation treatment industry. For instance, in November 2022, Kyowa Kirin Co. Ltd, a Japan-based biotechnology company, collaborated with Grünenthal GmbH, a Germany-based pharmaceutical company, to integrate solutions for patients. Through this partnership, they aspire to enhance the growth and global availability of a range of life-changing pain management medicines, including treatments for opioid-induced constipation, breakthrough cancer pain, and osteoporosis.

Which Leading Companies Dominate The Opioid-Induced Constipation Treatment Market Share?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Opioid-Induced Constipation Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2025, By The Business Research Company

Merkel Cell Carcinoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/merkel-cell-carcinoma-treatment-global-market-report

Basal Cell Carcinoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Crohns Disease Cd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795